Survivin, being both a genetic marker and a therapeutic target in HCC, has been associated with aberrant activation of the Wnt/β‐catenin pathway and inhibition of apoptotic processes (Yenkejeh et al. 2017). This evidence concerns the gene BIRC5 and hepatocellular carcinoma.